



Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

A. Passaro¹ · P. Mancuso² · S. Gandini³ · G. Spitaleri¹ · V. Labanca² · E. Guerini-Rocco^{4,5} · M. Barberis⁴ · C. Catania¹ · E. Del Signore¹ · F. de Marinis¹ · F. Bertolini²

Published online: 20 August 2019
© Federación de Sociedades Españolas de Oncología (FESEO) 2019

Correction to: Clinical and Translational Oncology
<https://doi.org/10.1007/s12094-019-02166-z>

Acknowledgements section was missing in the original published version. The Acknowledgement section read as follows:

Acknowledgements FB supported by AIRC IG 20109.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s12094-019-02166-z>.

✉ A. Passaro
antonio.passaro@ieo.it

- ¹ Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti, 435, 20141 Milan, Italy
- ² Laboratory of Hematology-Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- ³ Division of Epidemiology and Biostatistics, IEO, European Institute of Oncology IRCCS, Milan, Italy
- ⁴ Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology IRCCS, Milan, Italy
- ⁵ Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy